{
  "source": "PA-Notification-Omnipod.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1386-4\nProgram Prior Authorization/Notification\nMedication Omnipod® 5, TwiistTM\nP&T Approval Date 5/2022, 6/2023, 6/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nExternal insulin pumps are used for managing individuals with diabetes and deliver insulin by\ncontinuous subcutaneous infusion. OmniPod 5 is indicated for management of type 1 diabetes\nin persons aged 2 and older and in persons with type 2 diabetes aged 18 and older. Twiist is\nindicated in persons aged 6 and older with type 1 diabetes. Members will be required to meet\nthe following coverage criteria.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Omnipod 5 or Twiist will be approved for initial therapy based on both of the\nfollowing criteria:\na. One of the following:\n(1) For Omnipod 5: Diagnosis of diabetes\n(2) For Twiist: Diagnosis of Type 1 diabetes\n-AND-\nb. Both of the following:\n(1) Patient or caregiver is motivated to assume responsibility for self-care and\ninsulin management.\n(2) Patient or caregiver demonstrates knowledge of importance of nutrition\nincluding carbohydrate counting and meal planning.\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Omnipod 5 or Twiist will be approved for continuation of therapy based on the\nfollowing criteria:\na. Documentation of positive clinical response\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limi",
    " solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n• Coverage is not provided for indications unproven per medical benefit drug policy.\n4. References:\n1. American Diabetes Association. Diabetes Technology: Standard of Medical Care in\nDiabetes - 2024. Diabetes Care 2024;47(supplement 1):S126-S144.\n2. American College Of Clinical Endocrinology Consensus Statement: Comprehensive Type 2\nDiabetes Management Algorithm- 2023 Update. Endocrine Practice 29(2023)305-340.\nProgram Prior Authorization/Notification – Omnipod 5\nChange Control\n5/2022 New program.\n6/2023 Annual review. Updated references.\n6/2024 Annual review. Updated references.\n3/2025 Added Twiist to criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}